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Objective: To evaluate whether asthma and airway hyper-responsiveness are associated with
HIV infection.
Methods: We reviewed the literature on HIV-associated pulmonary diseases, pulmonary symp-
toms, and immune changes which may play a role in asthma. The information was analyzed
comparing the pre-HAART era to the post-HAART era data.
Results: HIV-seropositive individuals commonly experience respiratory complaints yet it is
unclear if the frequency of these complaints have changed with the initiation of HAART.
Changes in pulmonary function testing and serum IgE are seen with HIV infection even in
the post-HAART era. An increased prevalence of asthma among HIV-seropositive children
treated with HAART has been reported.
Conclusion: The spectrum of HIV-associated pulmonary disease has changed with the introduc-
tion of HAART. Current data is limited to determine if asthma and airway hyper-responsiveness
are more common among HIV-seropositive individuals treated with HAART.
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HIV-related pulmonary diseases have been recognized from
the onset of the AIDS epidemic.1,2 Initially, pulmonary-
related HIV diseases were predominantly infectious and
associated with a high morbidity and mortality.3 The
introduction of highly active antiretroviral therapy (HAART)
changed both HIV treatment and the spectrum of HIV-
associated diseases. Progression to acquired immune defi-
ciency (AIDS) and HIV-related mortality have declined since
HAART became the standard of care.4,5 A shift in the
epidemiology of HIV-associated infections has also occurred
in the era of HAARTwith decreased incidences in pulmonary
opportunistic infections6,7 and bacterial pneumonia8e10 in
developed countries. However, emerging data suggests an
increase in the incidence of HIV-related non-infectious
pulmonary conditions.
Recently, several studies have suggested an increased
incidence of asthma among HIV-seropositive individuals
receiving treatment with HAART.11e13 However, our
current understanding of the underlying mechanisms
accounting for this association and the role of anti-
retrovirals in HIV-associated pulmonary complications is
incomplete and we are unable to answer key questions
such as: What are the effects of HAART on the pulmonary
system? Does HAART modify the Th1/Th2 balance and thus
increase the risk of asthma? Why do persons with HIV, even
those treated with HAART, suffer a high burden of pulmo-
nary complaints? Are pulmonary symptoms among HIV
infected persons a clinical clue to underlying pathologic
changes which are increasing their risk for non-infectious
pulmonary diseases? The purpose of this paper is to
review the current literature on HIV and its potential
relationship to asthma. Since asthma itself is a complex
disease with varying phenotypes this paper will be divided
into sections where both the clinical aspects and the
science of HIV and asthma overlap.
HIV and respiratory symptoms
Asthma is a heterogeneous pulmonary disease character-
ized by episodic symptoms with several clinical phenotypes
now recognized.14 Respiratory symptoms such as wheezing,
chest tightness, dyspnea and cough are nonspecific but are
commonly associated with and can be clinical clues to the
diagnosis of asthma. This section will review the literature
to determine whether HIV-seropositive individuals suffer
from respiratory symptoms consistent with asthma and if
these symptoms changed after HAART.During the pre-HAART era an increased prevalence of
respiratory symptoms commonly associated with asthma,
notably cough and dyspnea was described among HIV-
seropositive individuals.15,16 Risk factors for these symp-
toms in the pre-HAART era included smoking, intravenous
drug use, low CD4 cell count, and previous pneumonia.15
Respiratory symptoms were also noted in persons without
a history of AIDS-related pulmonary infections. The exact
etiology of these symptoms remains unclear, but several
theories have been put forth to explain these data.
HIV infection alone appears to be related to dyspnea and
a few small studies have tried to explain this association.
These studies focused on functional mechanisms of dyspnea
with limited data on potential inflammatory mechanisms of
dyspnea similar to those postulated for asthma. In a study
by Schulz L et al.17 twenty-three HIV-seropositive males
without evidence of AIDS were compared to age- and
weight-matched HIV-seronegative males. HIV-infected
males were found to have a significantly lower maximal
inspiratory pressure, maximal expiratory pressure, and
respiratory muscle endurance as measured by incremental
threshold loading compared to their HIV-seronegative
counterparts. Additionally, a significant association
between dyspnea and respiratory muscle dysfunction
regardless of CD4 cell count was demonstrated.17
A more recent study from Nigeria evaluated the burden
of respiratory symptoms among HIV-seropositive individuals
who were not on HAART. They excluded smokers and those
exposed to biomass fumes which would limit those with
possible tobacco related lung disease. Among HIV-infected
subjects cough was the most common complaint, 48%, with
35% having cough with sputum production.18 Wheezing was
also found to be more prevalent among HIV-seropositive
individuals, 7% vs. 0% in HIV-seronegative individuals,
however there no statistically significant difference.18
While this study again demonstrates that HIV infection is
associated with a high prevalence of respiratory symptoms
it was limited by the lack of evaluation for opportunistic
infections.
While there is an overall paucity of data on the preva-
lence of respiratory symptoms consistent with asthma in
HIV-seropositive individuals in the HAART era, the studies to
date support an increased frequency of respiratory
complaints among HIV-seropositive individuals on HAART
versus those not on HAART.19,20 The first study to evaluate
respiratory symptoms in HIV-infected individuals during the
HAART era evaluated 234 subjects from a single, outpatient
HIV clinic.19 The majority of the subjects, 83.3%, were
receiving HAART at the time of the study. All subjects
underwent spirometry in addition to evaluation for
HIV and asthma 495respiratory symptoms. Thirty-one percent reported chronic
respiratory symptoms consistent with asthma: cough,
shortness of breath, and/or dyspnea on exertion. Cough
was the most common symptom, occurring in 23% of
subjects. Respiratory symptoms were more likely to occur
among current smokers, former smokers, history of intra-
venous (IV) drug use, advanced age, higher HIV viral loads,
history of bacterial pneumonia, and individuals with a lower
FEV1/FVC ratio.
19 Despite the significant burden of respi-
ratory symptoms 93.2% of the subjects had normal
spirometry, which would be more consistent with possible
asthma then primarily tobacco related lung disease. This
study was limited by the large male predominance, 82.5%,
high prevalence of current and/or former smokers, 59.8%,
and a large percentage of its subjects with a history of an
AIDS defining illness, 64.1%.19
Similar results were reported by Gingo et al.,20 who
evaluated 167 HIV-seropositive individuals at a single
outpatient HIV clinic. This cohort had a high prevalence of
HAART use, 80.7%, and 63.5% of the subjects complained of
at least one respiratory symptom with dyspnea and cough
being the most frequent, 43.7% and 37.1% respectively.20
HIV-associated risk factors of IV drug use and personal
smoking histories were again associated with a greater
likelihood of respiratory symptoms. Men who have sex with
men were less likely to have respiratory complaints. Several
others have also reported an increase in respiratory symp-
toms consistent with asthma among HIV-seropositive
persons in the post-HAART era however these studies
specifically looked at intravenous drug users (IVDU) in urban
populations21e23 and thus are limited due to the potential
for IV drug abuse to result in pulmonary disease.24,25
While these data suggest that respiratory symptoms
consistent with asthma are common in HIV-seropositive
individuals the true prevalence of these symptoms in the
HAART era is limited by the small number of individuals
studied. Additionally, it is not apparent if HAART increases
or decreases these symptoms (see Table 1). Furthermore,
no clear etiology for these symptoms has been determined,
but there have been attempts to evaluate lung function in
these individuals and correlate abnormalities with symp-
toms. Research evaluating the cellular and physiological
changes occurring after HIV infection and initiation of
antiretroviral therapy is needed to advance our under-
standing of HIV-associated respiratory symptoms and its
potential link to obstructive airway diseases such as asthma
and COPD.Table 1 Prevalence of respiratory symptoms among HIV-
seropositive individuals.
Pre-HAART16,60 Post-HAART20e22,24
Cough 40% 23e51%
Dyspnea on exertion 29e42% 16e44%
Shortness of breath 2% 3e7%
Wheezing 19e54% 19e36%
Sputum 42% 32e43%
Any respiratory
symptom
36% 32e64%HIV, IgE, and cytokine profiles
An association between asthma and IgE has long been
recognized.14,26,27 More recent focus has been on defining
various asthma phenotypes and allergic asthma in associa-
tion with atopy and elevated serum IgE levels is one well
accepted asthma phenotype.28e32 Interestingly, an eleva-
tion of serum IgE levels in HIV-seropositive individuals was
first recognized during the AIDS epidemic33,34 but it is not
yet know if there is an association between IgE levels and
the presence of symptoms or formal diagnosis of asthma. In
addition, the impact of HAART on IgE levels is unclear.
The etiology for elevated serum IgE in patients with HIV
is not completely understood. Serum IgE synthesis occurs in
B-cells with significant influence from T-regulatory cells. T-
helper cells are critical to the induction of IgE production
and alterations in T-helper cells secondary to HIV is
believed to contribute to abnormal IgE levels. Research has
shown a change in serum cytokine profiles in HIV-
seropositive individuals35e39 with an increase in IL-4 and
IL-10 and a decrease in IFN-g and IL-2 when compared to
HIV-seronegative control.37,40 This increase in Th2 cyto-
kines and decrease in Th1 cytokines leads to increased
synthesis of IgE from B-cells and is a cytokine profile
described in association with an allergic asthma pheno-
type41,42 and thus may be important in the apparent asso-
ciation of HIV infection and allergic asthma.
A further correlation between asthma and reconstitution
of CD4þ T-cells after antiretroviral therapy initiation has
been reported in HIV-seropositive children.12,13 Immune
reconstitution usually occurs within weeks to months after
starting HAART and represents an inflammatory
response.43,44 Typically, the inflammatory response is to
a pre-existing opportunistic infection however recent
research has also identified certain human leukocyte
antigen (HLA) and cytokine profiles associated with an
increased susceptibility to immune reconstitution dis-
ease.43e46 Furthermore, HIV infection itself can yield
immune reconstitution disease.47,48 Another interesting
observation is the report of 3 cases of successful treatment
of immune reconstitution disease with montelukast49 which
is also an effective medication for the treatment of
asthma.14,50 The underlying mechanism(s) for the immune
reconstitution syndrome and cytokine switching has yet to
be defined.
Thus, while elevations in serum IgE are common in HIV
both pre- and post-HAART, the exact prevalence and clin-
ical significance of this finding, particularly as it relates to
the potential development of asthma, is unknown.
HIV and bronchial hyperresponsiveness
A classic feature of asthma is bronchial hyper-
responsiveness (BHR) which is commonly measured via
bronchoprovocation testing such as a methacholine chal-
lenge test. The details of methacholine challenge testing
are beyond the scope of this review, however while it has
good sensitivity for the diagnosis of asthma in patients with
a high clinical probability of having asthma, there are some
limitations to the testing notably that some people with no
evidence of a pulmonary disease have a positive test.51e55
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data suggests 10%e16% of adults without pulmonary disease
will have a positive methacholine challenge test, with
increased rates noted in people with allergic rhinitis and
smokers.54 Despite these limitations, BHR determined by
methacholine testing remains a hallmark of asthma and is
often part of the evaluation of a patient with respiratory
symptoms consistent with asthma.42 Therefore, given the
previously noted increase in respiratory symptoms consis-
tent with asthma in HIV-seropositive people several studies
attempted to quantify the prevalence of BHR in HIV-
seropositive people, with additional attempts to correlate
BHR and respiratory symptoms, i.e. consistent with a diag-
nosis of asthma.
In the pre-HAART era, O’Donnell et al.56 analyzed
pulmonary function testing on 105 AIDS patients in the
Boston area from 1983 through 1986. Abnormally decreased
forced expiratory flow rates or significant response to
bronchodilators consistent with obstructive lung disease
was observed in 44% of their subjects.56 However, further
analysis of their data demonstrates a temporal relationship
between obstructive pattern on spirometry and acute
Pneumocystis pneumonia. Subsequently a study was done
comparing bronchial hyperresponsiveness to methacholine
challenge tests amongst HIV-seropositive individuals with
a mean CD4 cell count of 398 cells/mm3 and no evidence of
a respiratory infection versus HIV-seronegative individuals
of similar baseline demographics. The incidence of BHR was
greater in the HIV-seronegative cohort, 16% compared to 8%
in the HIV-seropositive subjects despite a greater preva-
lence of respiratory symptoms in the HIV-seropositive
individuals suggesting the previous findings of obstruction
were likely due to acute PCP infection.57 In addition, this
study was limited by the fact that all the participants were
former intravenous drug users and thus had significant risk
factors for lung disease which might confound the PFT
pattern.24,25
Wallace et al.58 performed methacholine challenge
testing during the pre-HAART era on 66 HIV-seropositive
predominantly male individuals. Their study found no
statistically significant difference in bronchial hyper-
responsiveness between the HIV-seropositive, and the HIV-
seronegative cohort matched for age, gender, race and
smoking history, 19.7% and 12.5% respectively. The most
recent study evaluating HIV infection and its potential link to
BHR occurred just prior to the introduction of HAART. This
study compared 248 HIV-seropositive males to 236 HIV-
seronegative males between the ages of 20 and 44 years
living in Montreal, Canada.59 They found a statistically
significant greater prevalence of wheezing (54.4% vs. 21.2%)
within the last year and BHR via methacholine challenge
testing (26.2% vs. 14.4%), in the HIV-seropositive cohort.
Further review of their results demonstrates a statistically
significant increase in positive skin testing and elevated
serum IgE among HIV-seropositive subjects with BHR
compared to HIV-seropositive subjects without BHR. This
study was limited by its focus on males and the higher
prevalence of smoking and previous diagnosis of asthma in
the HIV-seropositive cohort. Nonetheless, it does suggest
that amongst people with HIV infection there may be
a correlation between respiratory symptoms, serum IgE
levels and bronchial hyperresponsiveness. This constellationof clinical symptoms, IgE, and bronchial hyper-
responsiveness would be consistent with a diagnosis of
asthma.
There is no data on the prevalence of BHR among HIV-
seropositive individuals on HAART and future research is
needed to evaluate this question and determine if any
correlations exist between BHR, respiratory symptoms,
atopy and serum IgE levels consistent with an allergic
asthma phenotype.HIV and asthma
One of the first published studies exploring a potential
association between HIV and asthma in the post-HAART era
comes from the pediatric literature. A cross-sectional chart
review of 83 HIV-seropositive people ages 1e24 years
undergoing medical care at Texas Children’s Hospital in
2005 was performed.12 Individuals were assessed for
a diagnosis of asthma by ICD-9 codes. The authors found
a significant increase in the prevalence of asthma among
HIV-seropositive individuals, 34%, compared to both the
prevalence of asthma via a chart review of demographically
matched HIV-seronegative children receiving care at their
hospital, 2.9% and the reported prevalence of asthma in the
Houston area, 5%. They found no difference in CD4 cell
count or HIV viral load between HIV-seropositive asthmatics
and non-asthmatics, and only 6 of the 83 seropositive
subjects study met AIDS criteria by CD4 cell count. Inter-
estingly, 75% of their HIV-seropositive subjects were
receiving HAART therapy at the time of their asthma diag-
nosis. Subgroup analysis of 25 patients revealed a potential
association between asthma and immune reconstitution.
Immune reconstitution was defined as an increase in CD4þ
T-cells of greater than or equal to 5% while on HAART
therapy. They found 6 of 25 patients had documented
immune reconstitution within 2 years prior to their diag-
nosis of asthma. The mean time to asthma medications
after HAART initiation was 1.8 years (3.3 years) among
this subset.12 These data would thus suggest that inflam-
matory changes (immune reconstitution) induced by HAART
may result in the development of asthma in a subset of HIV-
seropositive patients.
Another larger retrospective study was performed on
prospectively collected data of children born to HIV-
seropositive individuals, the Women and Infants Trans-
mission Study (WITS). Children were enrolled in this
multicenter study in the United States and Puerto Rico at
the time of birth from 1988 to 2006, thus capturing both the
pre- and post-HAART eras. In this study asthma was defined
by the use of asthma medications which the authors listed
as: short-acting bronchodilators, long-acting bronchodila-
tors, inhaled corticosteroids, and leukotriene antagonists.
Foster et al.11 compared 2471 HIV-seronegative controls to
193 HIV-seropositive children and found a greater preva-
lence of asthma in HIV-seropositive children treated with
HAART (n Z 113) compared to HIV-seropositive children
who had never received HAART (n Z 80), 10.4% compared
to 3.8%. Further analysis of their cohorts did not demon-
strate any differences in sex, race/ethnicity, or socioeco-
nomic status. They also report a cumulative incidence of
asthma in HIV-seropositive children on HAART of 33.5%
HIV and asthma 497compared to 11.5% in HIV-seropositive children who were
never treated with HAART. They did not demonstrate
a significant difference in asthma prevalence between HIV-
seronegative children and HIV-seropositive children
receiving HAART. This may be due to the relatively high
prevalence of asthma reported in the HIV-seronegative
cohort, 10.5%.11
Similar prevalence rates of asthma were more recently
reported in a pediatric HIV-seropositive population from
Detroit, Michigan. In a retrospective chart review of 85 HIV
infected children ages 3e16 years, 24 of 85 children (28%)
met the criteria for the diagnosis of asthma based on
recorded clinical history, PFTs and medication use.13 The
authors do not report if any of the children were receiving
HAART therapy.
The current data on the prevalence of asthma in HIV-
seropositive adults on HAART is limited. Crothers et al.60
retrospectively reviewed data from veterans in the
Veterans Aging Cohort Study Virtual Cohort. Two large
cohorts, 3707 HIV-seropositive and 9980 HIV-seronegative,
were evaluated for the non-infectious pulmonary diseases
defined by ICD-9 codes. The cohorts were matched for age,
race and gender however, alcohol abuse, drug use and
hepatitis C were more common among the HIV-seropositive
cohort. Use of HAART in the HIV-seropositive group was 65%
and the median CD4 cell count in this cohort was 264 cells/
mm3. COPD and asthma were the most common non-
infectious pulmonary diseases among the HIV-seropositive
persons, 4.6% and 2% respectively. While COPD was noted
to have a higher prevalence among those infected with HIV
this was not true for asthma, as the prevalence of asthma in
the HIV-seronegative cohort was 2.4%. This study was
limited by the fact that the cohorts were predominately
male, 98% in both HIV-seropositive and HIV-seronegative,
with a greater percentage of smokers in the HIV infected
group, 80% vs. 76% (p < 0.001).
Overall, these retrospective studies suggest an increase
in a diagnosis of asthma in HIV-seropositive children. They
also suggest a further increase in asthma in those children
on HAART, with some data supporting a positive correlation
with immune reconstitution further suggesting alterations
in the host inflammatory response with HAART may increase
the incidence of asthma. There is a clear need for
prospective studies to determine if these findings are valid
and there is little data at present regarding the incidence of
asthma in HIV-seropositive adults on HAART.HIV and COPD
While there is limited data on HIV and asthma prevalence in
adults there is a large body of literature noting an associ-
ation between HIV and COPD, which shares many clinical
and physiologic parameters with asthma. The association
between HIV and airway obstruction and emphysema was
reported by several groups prior to the introduction of
antiretroviral therapy.61e64 A recent study again reported
an association between obstruction on spirometry and HIV.
Spirometry was performed on 100 HIV-seropositive Niger-
ians presenting to a teaching hospital afflicted with the
University of Nigeria.18 This cross-sectional study attemp-
ted to limit co-founding factors which could result inabnormal spirometry by excluding those with a prior diag-
nosis of COPD, asthma, bronchiectasis, pulmonary tuber-
culosis, congestive heart failure, spinal deformities, work
exposure to coal mines, quarries or wood workers, those
exposed to biomass fuels, and current or former smokers.
Obstruction on spirometry was found in 3% of the HIV-
seropositive cohort compare to 0% of the HIV-seronegative
cohort. None of the subjects were receiving HAART.
Despite these data there is still not a clear under-
standing of the underlying mechanism(s) accounting for the
development of COPD after HIV infection. Studies have
established an association between tobacco use, history of
pneumonia, advanced HIV disease or AIDS, and IV drug use
with airway obstruction and pneumonias specifically due to
Pneumocystis jiroveci were also associated with reversible
airway obstruction and bronchial hyperreactivity.59,65
Evaluation of this known association in the post-HAART
era has been sparse.
Antiretroviral therapy was associated with a decreased
FEV1/FVC in the study by George et al.
19 This study evalu-
ated 234 HIV-seropositive adults. The majority were male,
83% and Hispanic 53%. The major risk factor for HIV in this
cohort was men who have sex with men, 48%. While the
mean CD4 cell count was 371cells/ml, 64% of the partici-
pants had a history of AIDS including 16% with a history of
Pneumocystis pneumonia. Spirometry was normal in 93% of
the subjects. The prevalence of obstruction, defined as
FEV1/FVC < 0.70, was 6.8%. Although no statistically
significant association was discovered between airway
obstruction and subject characteristics there was a trend
toward HAART use and decreased FEV1/FVC ratio. In addi-
tion, HAART use was associated with obstruction indepen-
dent of age, smoking history, IV drug use, and previous
pneumonia.
Gingo et al., 2010 reported a similar association
between airway obstruction and antiretroviral therapy. One
hundred sixty seven HIV infected persons were evaluated
for respiratory symptoms, inhaler use and PFTs. Anti-
retroviral use was high in this study population with 80% on
HAART at the time of study enrollment. Irreversible airway
obstruction was noted in 21% of HIV-seropositive persons.20
Irreversible airway obstruction was associated with
advancing age, history of smoking, IV drug use, hepatitis B
and/or C, and antiretroviral therapy (p Z 0.04). No link
between CD4 T cell count, HIV viral load or duration of HIV
infection was established.
The association between irreversible airway obstruction
consistent with COPD and HIV continues to be a consistent
finding in the HAART era however the underlying mecha-
nism(s) for this association remain unfounded and an area
in need of additional research.Conclusion
It appears people with HIV have an increased incidence of
respiratory symptoms, elevated IgE, more response to
bronchoprovocation, and higher incidence of asthma than
seronegative controls. This may be increased with HAART,
but definite conclusions are difficult based on fewer studies
since the advent of HAART therapy. Possible explanations
for these associations may be direct viral effects, changes
498 J.A. Kynyk et al.to the TH1/TH2 balance, medication side effects, or
a manifestation of immune reconstitution syndrome.
A greater number of individuals are currently living with
HIV for increasingly longer periods since HAART. Physicians
need to be aware of and recognize the burden of non-
infectious respiratory symptoms namely dyspnea, cough,
wheezing, and chest tightness. This knowledge will allow
physicians to provide optimal care for these patients.
Additionally, awareness of these respiratory symptoms
among persons with HIV will aid in increasing our under-
standing on whether these symptoms are representative of
changes leading to certain pulmonary diseases such as
asthma and COPD. Advancing our knowledge on pulmonary
diseases associated with HIV and HAART use will require
further understanding of inflammatory and cellular changes
and requires physicians to take bedside observations back
to the bench.
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